PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia - Test2 - elhamkhani - TriplyDB

PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia

PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia

http://www.wikidata.org/entity/Q24299511

about

The granulocyte orphan receptor CEACAM4 is able to trigger phagocytosis of bacteria From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia Bioinformatic screening of autoimmune disease genes and protein structure prediction with FAMS for drug discovery Cistrome plasticity and mechanisms of cistrome reprogramming HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse The gene expression profiles in response to 102 traditional Chinese medicine (TCM) components: a general template for research on TCMs WIPI-dependent autophagy during neutrophil differentiation of NB4 acute promyelocytic leukemia cells.Characterisation of genome-wide PLZF/RARA target genes.The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells.Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells.MIR125B1 represses the degradation of the PML-RARA oncoprotein by an autophagy-lysosomal pathway in acute promyelocytic leukemia.Aberrant corepressor interactions implicated in PML-RAR(alpha) and PLZF-RAR(alpha) leukemogenesis reflect an altered recruitment and release of specific NCoR and SMRT splice variants.MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.PU.1 affects proliferation of the human acute myeloid leukemia U937 cell line by directly regulating MEIS1.Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide The significance of low PU.1 expression in patients with acute promyelocytic leukemia.Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia.Transcriptional repression of CDKN2D by PML/RARα contributes to the altered proliferation and differentiation block of acute promyelocytic leukemia cells.ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia Histone demethylase Kdm4b functions as a co-factor of C/EBPβ to promote mitotic clonal expansion during differentiation of 3T3-L1 preadipocytes.PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia.Structurally differentiated cis-elements that interact with PU.1 are functionally distinguishable in acute promyelocytic leukemia.From molecular interaction to acute promyelocytic leukemia: Calculating leukemogenesis and remission from endogenous molecular-cellular network.PU.1 controls the expression of long noncoding RNA HOTAIRM1 during granulocytic differentiation Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation.Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPα as a common target of TRIB1 and PML/RARA.Notch signaling in acute promyelocytic leukemia PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity.The molecular signature of oncofusion proteins in acute myeloid leukemia.Genome-wide functions of PML-RARα in acute promyelocytic leukaemia Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.Origins of aberrant DNA methylation in acute myeloid leukemia.Differentiation therapy of acute myeloid leukemia.Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: a TRAnsition to targeted therapies.Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer.Repression of CDKN2C caused by PML/RARα binding promotes the proliferation and differentiation block in acute promyelocytic leukemia.PML-RAR alpha induces the downmodulation of HHEX: a key event responsible for the induction of an angiogenetic response.Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

P2860

464fd657d6ed2d3439b02d6f0f486783bcbb9971 caaddf11dcfcc5b88ddae080d5c47859cfb23ad6 d9dc149b0f89c760c77bc6a83e3e959ec156893c

P248

Q24313103-AE6FA687-AC7E-41A9-8628-C6F5504E2E49 Q24605527-D56D8218-DE40-402F-A88C-A42CF5FF543C Q28654365-A049BA11-4860-415F-99D8-205BBA3C6679 Q28727255-E7AFDD2E-D7CE-48BC-A61A-AB2723887B7A Q33623363-EF7347C8-B14F-4BA9-BF5B-8466087D6C26 Q33673116-98F0C22A-3588-4AFF-949D-5145E69A5B80 Q34007677-F657E7BC-123C-4EA8-A7BF-BC994B21C6AA Q34031285-07834360-DD9F-410A-BBFE-233EDA7B6FC3 Q34041515-A224C59E-4206-4594-BED7-5AE9EB831D6E Q34267963-C549DB7A-9669-4EB7-96B3-25017BB61C42 Q34270770-0C4593F8-7632-47B8-AFAE-938D39BF3F65 Q34344666-FB2F601B-E270-42D1-B628-D9A69146E1CA Q34575940-D7C40E15-91FD-4A1D-830E-743EEDBDEEF7 Q35083272-843A5951-DC99-4537-99ED-37C78D805590 Q35541213-8D60107A-7DCD-4237-A92B-4EA6D20E1ECE Q35944525-3E950D0C-97D6-4F28-8188-E6D01BF37C6D Q35949253-89B025B4-E58C-42B0-9B91-066EF50F9988 Q36125630-758A214B-36DD-4B2D-8F72-B8A842413589 Q36259132-32934963-8966-4156-9AC6-D5D436DB2FBA Q36291101-05723CE8-000D-408F-94E3-DAC7BDB489CB Q36395611-ED284F32-155A-4800-9F20-33583221C1AD Q36418683-DE95DA08-2992-445C-BD59-111FC766E10A Q36430688-E6A21EDF-2DED-468F-BC3A-173C8E657469 Q36744733-57871275-0EDA-4A2D-A89E-4BED68896F80 Q36819689-99635046-33AF-4990-80CB-BD8CD389B7B1 Q36871408-F35195D7-6EA0-4046-A7E7-EA92751DC67F Q37216371-23A5A8E9-A521-4B9A-B55C-5D219DDE96BD Q37304117-73F7E0E4-5E0E-48EF-9E34-0D5D155A175F Q37414175-12DB2D41-7019-43F8-9775-C76DE0560F86 Q37686992-09F6E97B-C503-4C6C-9189-8B40EB62C565 Q37730254-C554FF24-E293-4CE0-91AB-B449D2AA25EA Q37829905-033E5456-6596-48C0-8A6C-CBD87CB99822 Q38020145-5B4CC798-7CE2-4D37-8F14-DEC387457719 Q38130091-7D3B3868-2503-4EE1-B3DE-CF6063ACF0C0 Q38161360-91668182-E3DA-4AFE-AAE5-E0B2FA06E5B3 Q38253382-B7F2217C-DF71-4CE3-8A30-2FD8CA5C8E57 Q38522309-9A5B9F5B-5415-4F85-83E6-A472FCB1FAF5 Q38728895-BBBA29DE-095E-4DA2-BA4E-7C1B5E52216E Q38780205-6F5FCC7C-1EEC-4CE0-9EE6-15F0A8175833 Q38876333-5EDD69F6-DB32-4F37-981E-F71C2FD15361

P2860

PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia

http://www.wikidata.org/entity/Q24299511

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

PML/RARalpha targets promoter ...... n acute promyelocytic leukemia

@ast

PML/RARalpha targets promoter ...... n acute promyelocytic leukemia

@en

PML/RARalpha targets promoter ...... n acute promyelocytic leukemia

@en-gb

PML/RARalpha targets promoter ...... n acute promyelocytic leukemia

@nl

type

label

PML/RARalpha targets promoter ...... n acute promyelocytic leukemia

@ast

PML/RARalpha targets promoter ...... n acute promyelocytic leukemia

@en

PML/RARalpha targets promoter ...... n acute promyelocytic leukemia

@en-gb

PML/RARalpha targets promoter ...... n acute promyelocytic leukemia

@nl

prefLabel

PML/RARalpha targets promoter ...... n acute promyelocytic leukemia

@ast

PML/RARalpha targets promoter ...... n acute promyelocytic leukemia

@en

PML/RARalpha targets promoter ...... n acute promyelocytic leukemia

@en-gb

PML/RARalpha targets promoter ...... n acute promyelocytic leukemia

@nl

P1433

Q24299511-47209A7B-0550-4D4B-ABAC-6A46C2F4B394

P1476

Q24299511-9CE3B4D5-527E-41B9-B817-A480DB6B10DF

P2093

Q24299511-13B96BB6-2561-41EE-BE34-AC9DF83E0D4E

Q24299511-326C39F3-C53A-497F-BB0E-EBB1AA9168BA

Q24299511-3A5B90F3-64FD-4DA8-A0B5-BEBE776E801C

Q24299511-3C0358AC-8C8E-455D-A010-9EE932CE0AE4

Q24299511-415316CF-A1A0-40A2-BFC6-2832F741D759

Q24299511-56ECA3AF-D7CA-4EC6-A513-0214C29C8136

Q24299511-78E69D78-F962-405D-8A49-BD7DD76FCCAD

Q24299511-8A9F3FA0-6D49-4C64-B07C-392940360ADE

Q24299511-8ADA69A8-3817-4F8D-B9A0-BC87881E8B98

Q24299511-B1BAEF6D-D894-4944-85EF-6AEB3651E7A8

P304

Q24299511-F5D1301F-7F94-4DBE-A002-E11C420C4D41

P31

Q24299511-834E698D-A9C0-45DC-9A3F-4F71898A9BA3

P3181

Q24299511-B3C860A0-AA09-4584-8E1B-88ABE95F382D

P356

Q24299511-D361C617-9723-41EE-A248-C03D83429505

P407

Q24299511-55B9FF54-58D2-438F-970F-33A601B19796

P433

Q24299511-0D4CF93A-4F96-4CEE-A36F-2C72095B4B0C

P478

Q24299511-152DED04-9957-4DC7-8FB8-14968D1FDC16

P577

Q24299511-C0D33B29-EB31-4F37-80A2-813C64694798

P5875

Q24299511-4E2914D9-E65B-47A3-B735-F83998BEAFD8

P698

Q24299511-F447D0C3-882C-4663-B883-1B3B4565E23A

P921

Q24299511-1EED7071-7ACA-4509-A5A8-05D063B586C8

P3181

P356

J.CCR.2009.12.045

P1433

P1476

PML/RARalpha targets promoter ...... n acute promyelocytic leukemia

@en

P2093

Fei Qiu

http://www.w3.org/2001/XMLSchema#string

Hai Fang

http://www.w3.org/2001/XMLSchema#string

Huasheng Xiao

http://www.w3.org/2001/XMLSchema#string

Ji Zhang

http://www.w3.org/2001/XMLSchema#string

Jianqing Mi

http://www.w3.org/2001/XMLSchema#string

Jiantao Shi

http://www.w3.org/2001/XMLSchema#string

Kankan Wang

http://www.w3.org/2001/XMLSchema#string

Maoxiang Qian

http://www.w3.org/2001/XMLSchema#string

Mark Minden

http://www.w3.org/2001/XMLSchema#string

Miaomiao He

http://www.w3.org/2001/XMLSchema#string

P304

186-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1863950

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CCR.2009.12.045

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41451407

http://www.w3.org/2001/XMLSchema#string

P698

20159610

http://www.w3.org/2001/XMLSchema#string

P921